Virginia Byers Kraus

Dr. Virginia Byers Kraus

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
VKVirginia Byers Kraus
Virginia Byers Kraus
FBFrancisco Blanco
Francisco Blanco
MEM. Englund
M. Englund
MKM.A. Karsdal
M.A. Karsdal
LLL.S. Lohmander
L.S. Lohmander

2 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CCChing-Heng Chou
Ching-Heng Chou
VJVaibhav Jain
Vaibhav Jain
JGJason Gibson
Jason Gibson
DADavid E. Attarian
David E. Attarian
CHCollin A. Haraden
Collin A. Haraden
VKVirginia Byers Kraus
Virginia Byers Kraus
We elucidated the molecular cross-talk between cartilage and synovium in osteoarthritis, the most widespread arthritis in the world, using the powerful tool of single-cell RNA-sequencing. Multiple cell types were identified based on profiling of 10,640 synoviocytes and 26,192 chondrocytes: 12 distinct synovial cell types and 7 distinct articular chondrocyte phenotypes from matched tissues. Intact cartilage was enriched for homeostatic and hypertrophic chondrocytes, while damaged cartilage was enriched for prefibro- and fibro-, regulatory, reparative and prehypertrophic chondrocytes. A total of 61 cytokines and growth factors were predicted to regulate the 7 chondrocyte cell phenotypes. Based on production by > 1% of cells, 55% of the cytokines were produced by synovial cells (39% exclusive to synoviocytes and not expressed by chondrocytes) and their presence in osteoarthritic synovial fluid confirmed. The synoviocytes producing IL-1beta (a classic pathogenic cytokine in osteoarthritis), mainly inflammatory macrophages and dendritic cells, were characterized by co-expression of surface proteins corresponding to HLA-DQA1, HLA-DQA2, OLR1 or TLR2. Strategies to deplete these pathogenic intra-articular cell subpopulations could be a therapeutic option for human osteoarthritis.

1 September 2016 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
VKVirginia Byers Kraus
Virginia Byers Kraus
GMG. McDaniel
G. McDaniel
JHJ.L. Huebner
J.L. Huebner
TST.V. Stabler
T.V. Stabler
CPC.F. Pieper
C.F. Pieper
PMP. Mitchell
P. Mitchell

1 May 2011 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
VKVirginia Byers Kraus
Virginia Byers Kraus
BBB. Burnett
B. Burnett
JCJ. Coindreau
J. Coindreau
SCS. Cottrell
S. Cottrell
DED. Eyre
D. Eyre
MTM. Todman
M. Todman

15 January 2015 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
EOEric W. Orlowsky
Eric W. Orlowsky
VKVirginia Byers Kraus
Virginia Byers Kraus
Although osteoarthritis (OA) has existed since the dawn of humanity, its pathogenesis remains poorly understood. OA is no longer considered a “wear and tear” condition but rather one driven by proteases where chronic low-grade inflammation may play a role in perpetuating proteolytic activity. While multiple factors are likely active in this process, recent evidence has implicated the innate immune system, the older or more primitive part of the body’s immune defense mechanisms. The roles of some of the components of the innate immune system have been tested in OA modelsin vivoincluding the roles of synovial macrophages and the complement system. This review is a selective overview of a large and evolving field. Insights into these mechanisms might inform our ability to identify patient subsets and give hope for the advent of novel OA therapies.

1 January 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
VKVirginia Byers Kraus
Virginia Byers Kraus
JCJamie E Collins
Jamie E Collins
DHDavid Hargrove
David Hargrove
ELElena Losina
Elena Losina
MNMichael Nevitt
Michael Nevitt
DHDavid Hunter
David Hunter
Objective To investigate a targeted set of biochemical biomarkers as predictors of clinically relevant osteoarthritis (OA) progression. Methods Eighteen biomarkers were measured at baseline, 12 months (M) and 24 M in serum (s) and/or urine (u) of cases (n=194) from the OA initiative cohort with knee OA and radiographic and persistent pain worsening from 24 to 48 M and controls (n=406) not meeting both end point criteria. Primary analyses used multivariable regression models to evaluate the association between biomarkers (baseline and time-integrated concentrations (TICs) over 12 and 24 M, transposed to z values) and case status, adjusted for age, sex, body mass index, race, baseline radiographic joint space width, Kellgren-Lawrence grade, pain and pain medication use. For biomarkers with adjusted p<0.1, the c-statistic (area under the curve (AUC)), net reclassification index and the integrated discrimination improvement index were used to further select for hierarchical multivariable discriminative analysis and to determine the most predictive and parsimonious model. Results The 24 M TIC of eight biomarkers significantly predicted case status (ORs per 1 SD change in biomarker): sCTXI 1.28, sHA 1.22, sNTXI 1.25, uC2C-HUSA 1.27, uCTXII, 1.37, uNTXI 1.29, uCTXIα 1.32, uCTXIβ 1.27. 24 M TIC of uCTXII (1.47–1.72) and uC2C-Human Urine Sandwich Assay (HUSA) (1.36–1.50) both predicted individual group status (pain worsening, joint space loss and their combination). The most predictive and parsimonious combinatorial model for case status consisted of 24 M TIC uCTXII, sHA and sNTXI (AUC 0.667 adjusted). Baseline uCTXII and uCTXIα both significantly predicted case status (OR 1.29 and 1.20, respectively). Conclusions Several systemic candidate biomarkers hold promise as predictors of pain and structural worsening of OA.